Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OPT007
MIFTS: 46

Optic Nerve Glioma

Categories: Cancer diseases, Neuronal diseases, Eye diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Optic Nerve Glioma

About this section

MalaCards integrated aliases for Optic Nerve Glioma:

Name: Optic Nerve Glioma 12 29 6 44 15 73
Glioma of the Optic Nerve 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4992
MeSH 44 D020339
NCIt 50 C4537
SNOMED-CT 68 254976006 404662003
UMLS 73 C0346326
Sources

Summaries for Optic Nerve Glioma

About this section
MalaCards based summary : Optic Nerve Glioma, also known as glioma of the optic nerve, is related to neurofibroma and childhood optic nerve glioma. An important gene associated with Optic Nerve Glioma is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Neuroscience and Interleukin-4 and 13 signaling. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 Optic nerve glioma (or optic glioma), a form of glioma which affects the optic nerve, is often one of... more...

Sources

Related Diseases for Optic Nerve Glioma

About this section

Diseases related to Optic Nerve Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 neurofibroma 29.7 MUC1 NF1 S100B SYP
2 childhood optic nerve glioma 12.3
3 neurofibromatosis-noonan syndrome 11.1
4 central nervous system teratoma 11.0 GFAP NES
5 anaplastic ganglioglioma 11.0 GFAP NES
6 pilomatrix carcinoma 11.0 ENO2 MUC1
7 hydrocephalus due to congenital stenosis of aqueduct of sylvius 11.0 MBP NES
8 localized hypertrophic neuropathy 10.9 MUC1 S100B
9 sclerosing perineurioma 10.9 MUC1 S100B
10 melanotic medulloblastoma 10.9 ENO2 GFAP
11 finger agnosia 10.9 ENO2 MBP
12 cutaneous leiomyosarcoma 10.9 GFAP MUC1
13 central nervous system germ cell tumor 10.9 GFAP NES
14 reticular perineurioma 10.9 MUC1 S100B
15 neonatal hypoxic and ischemic brain injury 10.9 ENO2 MBP
16 hydromyelia 10.9 S100B VIM
17 malignant peritoneal mesothelioma 10.9 MUC1 VIM
18 microcystic adenoma 10.9 ENO2 MUC1
19 non-functioning pituitary adenoma 10.8 MUC1 S100B
20 gemistocytic astrocytoma 10.8 GFAP S100B
21 cerebellar medulloblastoma 10.8 ENO2 GFAP
22 epulis 10.8 ENO2 VIM
23 middle cerebral artery infarction 10.8 ENO2 S100B
24 epithelioid leiomyosarcoma 10.8 ENO2 VIM
25 multicentric reticulohistiocytosis 10.8 TNFRSF11B VIM
26 clear cell meningioma 10.8 GFAP MUC1
27 duodenal somatostatinoma 10.8 ENO2 NF1
28 malignant triton tumor 10.8 NF1 S100B
29 malignant mixed mullerian tumor 10.7 MUC1 VIM
30 glioma 10.7
31 nodular hidradenoma 10.7 MUC1 VIM
32 primitive neuroectodermal tumor of the cervix uteri 10.7 ENO2 GFAP VIM
33 parachordoma 10.7 GFAP MUC1 VIM
34 endometrial mucinous adenocarcinoma 10.7 MUC1 VIM
35 meningeal melanocytoma 10.7 ENO2 MUC1 S100B
36 pericardial mesothelioma 10.7 ENO2 MUC1 VIM
37 spindle cell rhabdomyosarcoma 10.7 GFAP MUC1 S100B
38 bednar tumor 10.7 ENO2 S100B VIM
39 pilomatrixoma 10.7 ENO2 MUC1 S100B
40 fibrous meningioma 10.7 MUC1 S100B VIM
41 biphasic synovial sarcoma 10.7 MUC1 VIM
42 eccrine porocarcinoma 10.7 MUC1 S100B VIM
43 monophasic synovial sarcoma 10.7 MUC1 S100B VIM
44 osteochondroma 10.7 NES S100B VIM
45 plexiform schwannoma 10.7 ENO2 GFAP NF1
46 pleomorphic liposarcoma 10.7 MUC1 S100B VIM
47 spindle cell sarcoma 10.6 MUC1 S100B VIM
48 ureter small cell carcinoma 10.6 ENO2 SYP
49 dendritic cell tumor 10.6 MUC1 S100B VIM
50 secondary progressive multiple sclerosis 10.6 ENO2 MBP S100B

Graphical network of the top 20 diseases related to Optic Nerve Glioma:



Diseases related to Optic Nerve Glioma
Sources

Symptoms & Phenotypes for Optic Nerve Glioma

About this section

MGI Mouse Phenotypes related to Optic Nerve Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 FABP7 MTO1 GFAP NF1 LOX S100B
2 cardiovascular system MP:0005385 9.97 MIB1 MTO1 GFAP NF1 H2AFX LOX
3 cellular MP:0005384 9.96 ENO2 MIB1 MTO1 GFAP NF1 H2AFX
4 homeostasis/metabolism MP:0005376 9.93 FABP7 MTO1 GFAP NF1 H2AFX OPTN
5 mortality/aging MP:0010768 9.73 MIB1 MTO1 GFAP NF1 H2AFX OPTN
6 nervous system MP:0003631 9.32 ENO2 MIB1 FABP7 GFAP NF1 SYP
Sources

Drugs & Therapeutics for Optic Nerve Glioma

About this section

Drugs for Optic Nerve Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 85622-93-1 5394
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
4 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
5 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Early Phase 1
6
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
7
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
8
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
9
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
10
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
11
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
12
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
13
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
14
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
17
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
18
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
tipifarnib Investigational Phase 2 192185-72-1 159324
21
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
22 topoisomerase I inhibitors Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 2,Phase 1
24 Angiogenesis Inhibitors Phase 1, Phase 2,Phase 2
25 Angiogenesis Modulating Agents Phase 1, Phase 2,Phase 2
26 Anti-Bacterial Agents Phase 2,Phase 1
27 Immunosuppressive Agents Phase 2,Phase 1
28 Anti-Infective Agents Phase 1, Phase 2,Phase 2
29 Protein Kinase Inhibitors Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
31 Ether Phase 2,Phase 1
32 interferons Phase 2
33 Hematoporphyrin Derivative Phase 2,Phase 1
34 Hematoporphyrins Phase 2,Phase 1
35 Dermatologic Agents Phase 2,Phase 1
36 Dihematoporphyrin Ether Phase 2,Phase 1
37 Anthelmintics Phase 1, Phase 2
38 Photosensitizing Agents Phase 2,Phase 1
39 Piperazine citrate Phase 1, Phase 2
40 Anticonvulsants Phase 1, Phase 2
41 Interferon-alpha Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Antiviral Agents Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 Pharmaceutical Solutions Phase 2
46 Micronutrients Phase 2
47 Nicotinic Acids Phase 2
48 Trace Elements Phase 2
49 Vitamin B Complex Phase 2
50 Vitamins Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
2 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
3 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
4 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
5 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
6 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
7 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
8 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Recruiting NCT02839720 Phase 2 Selumetinib
9 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
10 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
11 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
12 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
13 Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Not yet recruiting NCT03326388 Phase 1, Phase 2 Selumetinib
14 Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Terminated NCT01338857 Phase 2 Sorafenib (Nexavar)
15 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
16 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
17 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
18 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
19 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
20 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
21 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
22 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
23 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
24 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
25 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
26 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
27 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide
28 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
29 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting NCT02780804 Phase 1 Entinostat
30 Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Active, not recruiting NCT02415153 Phase 1 Pomalidomide
31 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Active, not recruiting NCT00638898 Phase 1 busulfan;melphalan;topotecan hydrochloride
32 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
33 Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. Unknown status NCT02078401
34 Natural History Study of Patients With Neurofibromatosis Type I Recruiting NCT00924196
35 PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Active, not recruiting NCT01800032
36 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Active, not recruiting NCT00919750
37 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Terminated NCT02175745 Not Applicable 18F-fluoro-dihydroxyphenylalanine
38 Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas Withdrawn NCT02976441 Early Phase 1 Temozolomide
39 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable

Search NIH Clinical Center for Optic Nerve Glioma

Cochrane evidence based reviews: optic nerve glioma

Sources

Genetic Tests for Optic Nerve Glioma

About this section

Genetic tests related to Optic Nerve Glioma:

# Genetic test Affiliating Genes
1 Optic Nerve Glioma 29
Sources

Anatomical Context for Optic Nerve Glioma

About this section

MalaCards organs/tissues related to Optic Nerve Glioma:

41
Brain, T Cells, Spinal Cord, Eye, Colon
Sources

Publications for Optic Nerve Glioma

About this section

Articles related to Optic Nerve Glioma:

(show top 50) (show all 87)
# Title Authors Year
1
Progressive optic nerve glioma: orbital biopsy technique using a surgical navigation system. ( 29426453 )
2018
2
Isolated Optic Nerve Glioma in Children With and Without Neurofibromatosis: Retrospective Characterization and Analysis of Outcomes. ( 29502465 )
2018
3
Optic Nerve Glioma in Two Sisters with Family History of Neurofibromatosis Type 1. ( 29294511 )
2018
4
Optic nerve glioma with complete intraocular extension. ( 27830210 )
2016
5
Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome. ( 27230830 )
2016
6
Childhood Optic Nerve Glioma: Vision Loss Due to Biopsy. ( 27046034 )
2016
7
Teaching NeuroImages: Optic nerve glioma with perineural arachnoid gliomatosis in a patient with neurofibromatosis-1. ( 25825471 )
2015
8
Optic nerve glioma: an update. ( 24736941 )
2014
9
Anisometropia in children with neurofibromatosis type 1 and unilateral optic nerve glioma. ( 24924279 )
2014
10
Aggressive Low-Grade Optic Nerve Glioma in Adults. ( 27928317 )
2014
11
Optic nerve glioma: A great mimicker. ( 24575324 )
2014
12
An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis). ( 25411512 )
2014
13
Optic nerve glioma: case series with review of clinical, radiologic, molecular, and histopathologic characteristics. ( 24762952 )
2014
14
Optic nerve glioma treatment with fractionated stereotactic radiotherapy. ( 23495806 )
2013
15
Surgical management of an optic nerve glioma with perineural arachnoidal gliomatosis growth pattern. ( 23149617 )
2013
16
Fractionated stereotactic radiotherapy using Novalis for confined intra-orbital optic nerve glioma in pediatric patient. ( 23338672 )
2013
17
Accuracy of MRI in defining tumor-free margin in optic nerve glioma surgery. ( 23715516 )
2013
18
Myopia associated with optic nerve gliomas in neurofibromatosis type 1. ( 22370674 )
2012
19
Morning glory disc anomaly in association with ipsilateral optic nerve glioma. ( 22893090 )
2012
20
Diagnosis and management of optic nerve glioma. ( 22071462 )
2011
21
Neovascular glaucoma following stereotactic radiosurgery for an optic nerve glioma: a case report. ( 20714392 )
2010
22
Diagnostic pitfall: optic neuritis mimicking optic nerve glioma. ( 18721230 )
2009
23
Optic nerve sheath fenestration for an isolated optic nerve glioma. ( 18930671 )
2009
24
Multiple wedge-shaped retinal nerve fiber layer defects in a patient with optic nerve glioma in the contralateral eye: case report. ( 19820802 )
2009
25
Electrophysiological monitoring in a patient with an optic nerve glioma. ( 18301934 )
2008
26
Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. ( 19033845 )
2008
27
Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma. ( 18157537 )
2008
28
Adult optic nerve glioma presenting as central retinal vein occlusion. ( 25390231 )
2007
29
Retrobulbar cysticercosis masquerading as optic nerve glioma. ( 17510876 )
2007
30
Malignant optic nerve glioma (glioblastoma multiforme): A case report and literature review. ( 17111679 )
2006
31
Significant improvement of visual functions after removal of an intracranial giant optic nerve glioma revealing exophytic growth: case report. ( 16575300 )
2006
32
Optic nerve glioma in neurofibromatosis-I. ( 15695867 )
2005
33
Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. ( 15622533 )
2005
34
Optic nerve glioma and optic neuritis mimicking one another: case report. ( 15987555 )
2005
35
Unilateral adult malignant optic nerve glioma. ( 15085353 )
2004
36
Optic nerve glioma and colonic polyposis: report of a new association. ( 15384896 )
2004
37
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. ( 14695164 )
2003
38
Malignant optic nerve glioma: metastases to the spinal neuraxis. Case illustration. ( 12546402 )
2003
39
Optic nerve glioma in a patient with von Hippel-Lindau syndrome. ( 12580276 )
2003
40
Optic nerve glioma manifesting as intratumoral hemorrhage in a pregnant woman--case report. ( 14705324 )
2003
41
Recent advances in optic nerve glioma with a focus on the young patient. ( 14624073 )
2003
42
Optic nerve glioma. ( 12956473 )
2003
43
Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. ( 14635617 )
2003
44
Optic nerve glioma. ( 11374634 )
2001
45
Optic nerve glioma in infancy: a case report of the youngest patient in Thailand. ( 11529326 )
2001
46
Growth hormone hypersecretion in a girl with neurofibromatosis type 1 and an optic nerve glioma: resolution following chemotherapy. ( 11146372 )
2000
47
Bilateral optic nerve glioma. ( 10708361 )
1999
48
Choroidal neovascular membrane as a feature of optic nerve glioma. ( 9279953 )
1997
49
Optic nerve glioma mimicking an optic nerve meningioma. ( 8884101 )
1996
50
Primary benign tumors of the orbital cavity: comparative data in a series of patients with optic nerve glioma, sheath meningioma, or neurinoma. ( 8607065 )
1996
Sources

Variations for Optic Nerve Glioma

About this section

ClinVar genetic disease variations for Optic Nerve Glioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NF1 NM_000267.3(NF1): c.4267A> G (p.Lys1423Glu) single nucleotide variant Pathogenic rs137854550 GRCh37 Chromosome 17, 29585518: 29585518
2 NF1 NM_000267.3(NF1): c.4267A> G (p.Lys1423Glu) single nucleotide variant Pathogenic rs137854550 GRCh38 Chromosome 17, 31258500: 31258500
3 NF1 NM_000267.3(NF1): c.2041C> T (p.Arg681Ter) single nucleotide variant Pathogenic rs768638173 GRCh38 Chromosome 17, 31226474: 31226474
4 NF1 NM_000267.3(NF1): c.2041C> T (p.Arg681Ter) single nucleotide variant Pathogenic rs768638173 GRCh37 Chromosome 17, 29553492: 29553492
5 NF1 NM_000267.3(NF1): c.1721+3A> G single nucleotide variant Pathogenic rs1057518904 GRCh38 Chromosome 17, 31221932: 31221932
6 NF1 NM_000267.3(NF1): c.1721+3A> G single nucleotide variant Pathogenic rs1057518904 GRCh37 Chromosome 17, 29548950: 29548950

Cosmic variations for Optic Nerve Glioma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM476 BRAF central nervous system,optic nerve,glioma,NS c.1799T>A p.V600E 7:140753336-140753336 9
Sources

Expression for Optic Nerve Glioma

About this section
Search GEO for disease gene expression data for Optic Nerve Glioma.
Sources

Pathways for Optic Nerve Glioma

About this section

Pathways related to Optic Nerve Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
12.14 ENO2 FABP7 GFAP MAP2 MBP NF1
2
Interleukin-4 and 13 signaling 66
11.55 MUC1 TP53 VIM
3
Spinal Cord Injury 1
11.54 GFAP MBP TP53 VIM
4
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.47 GFAP NES VIM
5
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.06 FABP7 GFAP MAP2 NES S100B SYP
Sources

GO Terms for Optic Nerve Glioma

About this section

Cellular components related to Optic Nerve Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 9.13 FABP7 GFAP MAP2
2 neuronal cell body GO:0043025 9.02 ENO2 FABP7 MAP2 MBP S100B

Biological processes related to Optic Nerve Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 astrocyte development GO:0014002 9.37 GFAP VIM
2 intermediate filament organization GO:0045109 9.32 GFAP VIM
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
4 extracellular matrix organization GO:0030198 9.26 GFAP LOX NF1 TNFRSF11B
5 Bergmann glial cell differentiation GO:0060020 9.16 GFAP VIM
6 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Optic Nerve Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 GFAP OPTN S100B SYP TP53 VIM
2 structural molecule activity GO:0005198 8.92 GFAP MAP2 NES VIM
Sources

Sources for Optic Nerve Glioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....